Abstract
AbstractThe International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) adopted Guideline M10 entitled "Bioanalytical Method Validation and Study Sample Analysis" in May 2022. In October 2023, approximately one year after the adoption of the ICH M10 guideline, a "Hot Topic" session was held during the AAPS PharmSci 360 meeting to discuss the implementation of the guideline. The session focused on items the bioanalytical community felt were challenging to implement or ambiguous within the guideline. These topics included cross-validation, parallelism, comparative bioavailability studies, combination drug stability, endogenous analyte bioanalysis, and dilution QCs. In addition, the regulatory perspective on the guideline was presented. This report provides a summary of the Hot Topic session.
Graphical Abstract
Publisher
Springer Science and Business Media LLC
Reference12 articles.
1. ICH, Guideline M10 - Bioanalytical Method Validation and Study Sample Analysis. 2022. https://database.ich.org/sites/default/files/M10_Guideline_Step4_2022_0524.pdf. Accessed 6 Sept 2024.
2. EMA, guideline on bioanalytical method validation. 2011. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf. Accessed 6 Sept 2024.
3. US FDA, Bioanalytical method validation guidance for industry. 2018 https://www.fda.gov/media/70858/download. Accessed 6 Sept 2024.
4. Briggs RJ, et al. Method transfer, partial validation, and cross-validation: recommendations for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPSJ. 2014;16:1143–8.
5. Heinig K, Miya K, Kamei T, Guerini E, Fraier D, Yu L, Bansal S, Morcos P. Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment. Bioanalysis. 2016;8:1465–79.